Sitagliptin therapy led to a 0.72% reduction in mean A1C levels at 54 weeks, while glipizide treatment resulted in an 0.87% decrease among type 2 diabetes patients with end-stage renal disease who require dialysis, according to a study in the American Journal of Kidney Diseases. Researchers also found the incidence rates of symptomatic hypoglycemia were 6.3% in the sitagliptin group and 10.8% in the glipizide group.
Drugs show efficacy in patients with type 2 diabetes, ESRD
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||